CDSCO gives nod to Strides Pharma to manufacture, Export Sputnik Light

The drug product block of the facility is designed to produce up to 720 million doses in a year.


Last Updated on December 23, 2021 by The Health Master

Bengaluru: Stelis Biopharma Limited, the biotech division of Strides Pharma Science Limited, has commissioned its large-scale fully integrated vaccine manufacturing facility at Bengaluru, India.

The facility was successfully inspected by the Central Drugs Standard Control Organization (CDSCO). Stelis has also received an initial Export No Objection Certificate (NOC) from CDSCO to export up to 50 million doses of the Sputnik Light vaccine.

In March 2021, Stelis partnered with the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) to produce and supply the Russian Sputnik vaccine. Stelis has now started manufacturing the Sputnik Light vaccine at a commercial scale, and as previously committed, the Company is on track to commercialize this vaccine for Global markets in Q4FY22.

Stelis’ greenfield vaccine facility was built in a record time of less than 200 days with a best in class design and modularity to cater to several vaccine formats. It is also one of the largest viral vector manufacturing sites with a bespoke design for producing the Russian Sputnik Vaccine.

In its current state, the site can offer flexible technologies to manufacture lentivirus, adenovirus and retrovirus products/ vaccines along with adherent and suspension-based processes.

The site is equipped with a 40,000L Drug Substance bioreactor capacity at a 2,000L scale, using Single-Use Bioreactor technology, providing optimum flexibility and cost-effectiveness for any volume demand.

The drug product block of the facility is designed to produce up to 720 million doses in a year.

Strides is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets.

The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida).

CDSCO panel’s nod to Sun Pharma for Rosuvastatin Sprinkle Capsules

Sun Pharma gets CDSCO panel nod for FDC Brinzolamide, Timolol, Pot Sorbate

CDSCO Panel gives nod to Sun Pharma’s Dapagliflozin, Glimepiride, Metformin FDC

IPC adds 15 new impurities Reference Substances and 11 IP Reference…

Drug alert: 22 out of 1102 samples declared as NSQ in…

Govt is able to collect data on only 237 Medical devices

IPC’s new 2nd edition of Guidance Manual for Monographs Development

USFDA completes audit at MSN Pharma with zero observations

Govt approves PLI scheme to promote domestic API production

Govt is working on policy to encourage research in Pharma sector

Pharmexcil to organize seminar on ‘Reinvigorating India’s Pharma Exports’

Haryana is the best state for setting up Pharma Industries: HM

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon

Enter your email address:

Delivered by FeedBurner